Navigation Links
Raven Announces Continued Enrollment of Phase 1/2a Clinical Trial of RAV12 Therapeutic Antibody for Treatment of Adenocarcinomas
Date:11/27/2007

SOUTH SAN FRANCISCO, Calif., Nov. 27 /PRNewswire/ -- Raven biotechnologies, inc., a privately held company focused on the development of monoclonal antibody therapeutics (MAbs) for cancer, today announced it is continuing to enroll new patients in the maximum tolerated dose cohort expansion segment of its Phase 1/2a trial for patients with cancers of the gastrointestinal tract that express the RAAG12 antigen.

RAAG12 is a glycotope (sugar structure) that is widely found on the surface of tumor cells of many kinds of cancer, particularly cancers of the gastrointestinal tract (adenocarcinomas of gastroesophageal, pancreatic and colorectal origin). RAV12, Raven's lead clinical monoclonal antibody drug candidate, targets the RAAG12 antigen.

This segment of the trial will yield additional information about the safety of the drug and define the pharmacokinetics of the antibody.

The appropriate dose and schedule of RAV12 was chosen in a dose-escalation segment of the Phase 1/2a trial that involved 33 patients. This trial revealed that a fractionated dosing regimen provided an improved safety profile for the antibody. Raven is now enrolling patients in a second segment of the trial in which all patients are receiving the recommended dose and schedule of drug. Information from the Phase 1/2a trial will be supporting the dosing in a Phase 2 study in pancreatic cancer, the next clinical trial scheduled for RAV12.

The trial is being conducted at five institutions in the United States: The Sarah Cannon Cancer Center in Nashville, TN; The Fox Chase Cancer Center in Philadelphia, PA; Premiere Oncology in Santa Monica, CA; Georgetown University Medical Center in Washington, DC; and The University of Miami Medical Center in Miami, FL.

About RAV12

RAV12 is a novel, chimeric monoclonal antibody that is directed against a primate-specific glycotope (sugar structure) that is widely displayed on the surfaces of tumor cells, particularly tho
'/>"/>

SOURCE Raven biotechnologies, inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
2. Raven Announces Phase 1 Clinical Trial Results of RAV12 Therapeutic Antibody for Treatment of Adenocarcinomas
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
8. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
9. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
10. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
11. Amicus Therapeutics Announces Second Quarter 2007 Financial Results

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2009)... , BOSTON, Dec. 1 /PRNewswire-FirstCall...ion (Nasdaq: PRXL ), a leading global biopharmace...sion on innovative approaches to drug development ...a Pacific Conference, being held December 1-3, 200...XEL is a sponsor of the conference, which is focus...
(Date:11/30/2009)... , SAN CARLOS, Calif., Nov. 30 /PRNewswire-Fi...oday announced the promotion of Lorianne Masuoka, ...ficer. Dr. Masuoka will report directly to Nektar.... Robin. ,, "Lorianne,s outstanding leadershi...gies have been instrumental in rapidly advancing N...
(Date:11/30/2009)..., TORONTO, Nov. 30 The Special ... ("Patheon" or the "Company") (TSX: PTI) and JLL P...ngs, LLC (collectively, "JLL"), today announced th...ent agreement in respect of the pending legal acti...ovides among other things that: ,, until March...
Breaking Medicine Technology:PAREXEL Expert To Lead Panel on Innovative Drug Development in Asia at Partnerships in Clinical Trials Asia Pacific Conference 2PAREXEL Expert To Lead Panel on Innovative Drug Development in Asia at Partnerships in Clinical Trials Asia Pacific Conference 3PAREXEL Expert To Lead Panel on Innovative Drug Development in Asia at Partnerships in Clinical Trials Asia Pacific Conference 4Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Senior Vice President and Chief Medical Officer 2Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Senior Vice President and Chief Medical Officer 3Patheon and JLL Partners Announce Litigation Settlement 2Patheon and JLL Partners Announce Litigation Settlement 3New method separates cancer cells from normal cells 8842 1New method separates cancer cells from normal cells 8842 2Pelosi Statement on President Obamas Speech to AMA on Urgent Need for Health Care Reform 48948 1American Hospital Management Company Announces the Opening of the New HOSPITAL UNIVERSITARIO DEL RIO HOSPIRIO in Cuenca Ecuador 48945 1American Hospital Management Company Announces the Opening of the New HOSPITAL UNIVERSITARIO DEL RIO HOSPIRIO in Cuenca Ecuador 48945 2
...Term Clinical Study Confirms Effectiveness of Auto...e results of a two-year,representative study of kn...y renowned journal "Osteoarthritis and Cartilage",... therapy, in which,anti-inflammatory proteins obta...o the arthritic joint., Researchers at Heinrich H...
...l to Examine New Therapeutic Platform in Patients ... Edema-, SUNNYVALE, Calif., Aug. 5 Icon Biosci...maceutical company, announced today that,enrollmen... to assess the,safety and efficacy of its lead pro...edema. This multi-site trial enrolled patients wit...
Other Medicine Technology:Orthokine Treatment is Effective for Knee Arthritis, Even After Two Years 2Icon Bioscience Completes Enrollment in Phase I Study of Novel Ophthalmic Drug Candidate 2
(Date:12/1/2009)...dose radiation from annual mammography screening m...ic or familial predisposition to breast cancer, ac...eeting of the Radiological Society of North Americ...cancer, screening is very important, but a careful...aphy for screening young women, particularly under...
(Date:12/1/2009)...udy using functional magnetic resonance imaging (f...ts who were exposed to lead as children incur perm...ay at the annual meeting of the Radiological Socie...d is that no region of the brain is spared from le...cil, Ph.D., imaging scientist at Cincinnati Childr...
(Date:12/1/2009)..., December 1, 2009 Adolescent obesity is a major ...y three children, resulting in 4-5 million overwei...ed in the December 2009 issue of the Journal of t...luated differences in weight control behaviors, in...aring overweight adolescents who lost weight and t...
(Date:11/30/2009)...CAGO, Dec. 1 Being overweight as a...ne, according to a study presented today at the an...America (RSNA). ,, "This is the first study to ...dex (BMI) and disc abnormalities in children," sai...ellow in diagnostic neuroradiology at The Children...
(Date:11/30/2009)...CAGO, Dec. 1 High-frequency ultras...een cancerous and benign skin conditions, accordin... of the Radiological Society of North America (RSN...aphy has the potential to improve the efficiency o.... Siegel, M.D., vice chairman of the Department of...
Breaking Medicine News(10 mins):Health News:Mammography may increase breast cancer risk in some high-risk women 2Health News:Childhood lead exposure causes permanent brain damage 2Health News:Investigators identify successful weight control strategies for adolescents 2Health News:Overweight Children may Develop Back Pain and Spinal Abnormalities 2Health News:Special Ultrasound Accurately Identifies Skin Cancer 2Health News:Special Ultrasound Accurately Identifies Skin Cancer 3
...America Line has surpassed the,million-dollar mark...e,Cure(R) via its On Deck for the Cure program, ea...llar Council. The line will celebrate the mileston...in 2006, On Deck for the Cure has raised nearly,$1...
... PathNet Esoteric,Laboratory Institute Main Labora...creditation by the Commission on Laboratory Accred...AP), based on the results of a,recent on-site insp...s,being provided." PathNet Esoteric Lab Institute ...
... International Representation, WASHINGTON, Aug. 1...today participation of 37 Supporting Partner,Organ...a, Canada, Ireland,Israel, New Zealand, Russia and...tion to their respective memberships,and are helpi...
...t Pacific Corporation, one of,the Northwest,s best...,added a new integrated 3-D charting software prog...ffices to achieve a paperless and chartless,enviro...c,Corporation CEO Jack Scott. "We can also store v...
... IDE in a Key Position for Competing for Similar ... on the Australian Continent and Strengt...August 12 IDE Technologies, jointly,owned (50:50)...llion Euros to a major industrial client in Austra...
...Competition Aims To Raise Record Funds For the Pe...tal Los Angeles, LOS ANGELES, Aug. 12 Los Angele...st athletes, celebrities and philanthropists,when ...autica Malibu Triathlon will put their skills to,t...
Other Medicine News:Health News:Holland America Line Program Surpasses $1 Million Raised for Susan G. Komen for the Cure(R) 2Health News:Holland America Line Program Surpasses $1 Million Raised for Susan G. Komen for the Cure(R) 3Health News:Holland America Line Program Surpasses $1 Million Raised for Susan G. Komen for the Cure(R) 4Health News:PathNet Esoteric Laboratory Institute Main Laboratory Receives Accreditation From College of American Pathologists 2Health News:AdvaMed 2008 Supporting Partner Organizations Up 30% Over Last Year 2Health News:AdvaMed 2008 Supporting Partner Organizations Up 30% Over Last Year 3Health News:AdvaMed 2008 Supporting Partner Organizations Up 30% Over Last Year 4Health News:Oregon-Based First Pacific Corporation Launches New Integrated 3-D Charting Program for Dentists 2Health News:IDE Technologies Signs Contract Worth Over 100 Million Euros to Supply a Desalination Plant to Australia 2Health News:Nautica Malibu Triathlon, Presented By Toyota, Showcases Athleticism, Philanthropy in 22nd Year 2Health News:Nautica Malibu Triathlon, Presented By Toyota, Showcases Athleticism, Philanthropy in 22nd Year 3Health News:Nautica Malibu Triathlon, Presented By Toyota, Showcases Athleticism, Philanthropy in 22nd Year 4Health News:Nautica Malibu Triathlon, Presented By Toyota, Showcases Athleticism, Philanthropy in 22nd Year 5
Infinity Glucose Oxidase (Liquid)
...ended for the in vitro quantitative determination ...powder reagent proprietary formulation not only pr...convenience, but ensures excellent precision and c... suitable for manual use or on automated clinical ...
Velo® 300M Wavefront Lens Analyzer
Pulse Oximeter Repair
Medicine Products: